Positive Progress for OSE Immunotherapeutics and ARTEMIA Trial
OSE Immunotherapeutics has recently received encouraging news regarding its pivotal Phase 3 ARTEMIA trial, which evaluates Tedopi® in patients with non-small cell lung cancer (NSCLC). This recommendation came from the Independent Data Monitoring Committee (IDMC), which has been overseeing the trial's progress and safety evaluation.
Key Recommendations from the IDMC
The IDMC plays a vital role in clinical trials by ensuring the safety and efficacy of the treatment being tested. The committee, which includes esteemed international experts in lung cancer, met to review the ongoing data from the ARTEMIA trial, ultimately concluding that the study could proceed without alterations. Their commitment to patient safety and rigorous analysis reflects the standards upheld within the biomedical field.
Expert Insights from OSE Immunotherapeutics
Dr. Silvia Comis, who serves as the Chief Clinical and Medical Research Officer at OSE Immunotherapeutics, expressed her satisfaction with the IDMC’s decision. The trial currently has around 120 patients enrolled, and according to projections, recruitment meets anticipated targets set for the following year. This alignment emphasizes the company’s strategic planning and execution in patient enrollment.
Details of the ARTEMIA Trial
The ARTEMIA trial commenced in late 2024, aimed at comparing the effectiveness of Tedopi® monotherapy against the standard treatment, docetaxel, for HLA-A2 positive patients. These patients have typically shown secondary resistance to commonly used immune checkpoint inhibitors. Conducted across multiple international sites, the trial's design and comprehensive review process suggest robust validity and potential for impactful results in the NSCLC treatment landscape.
Future Review and Milestones
Another IDMC review is expected in the first quarter of 2026, as the trial progresses. The study is anticipated to conclude its recruitment phase by the end of 2026, with the primary endpoint for overall survival results projected for the year's first quarter in 2028.
The Mission of OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotech enterprise dedicated to pioneering treatments in immuno-oncology and immuno-inflammation. Their mission is to meet the pressing needs within the patient community by developing innovative therapies. Collaborating closely with top-tier academic institutions and other pharmaceutical partners, OSE’s focus remains on transforming the treatment landscape for serious diseases.
Contact Information for OSE Immunotherapeutics
For those interested in learning more about OSE Immunotherapeutics or its latest developments, the company provides contact details for its representatives:
Fiona Olivier
fiona.olivier@ose-immuno.com
Sylvie Détry
sylvie.detry@ose-immuno.com
French Media Contact
FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact
Rooney Partners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
Frequently Asked Questions
What is the ARTEMIA trial about?
The ARTEMIA trial evaluates the efficacy of Tedopi® as a treatment for non-small cell lung cancer, comparing it to standard care.
Who oversees the ARTEMIA trial?
The trial is monitored by an Independent Data Monitoring Committee which ensures safety and efficacy throughout its duration.
What did the IDMC recommend for the ARTEMIA trial?
The IDMC recommended that the trial continue without modifications, based on their review of trial data.
When did the ARTEMIA trial commence?
The ARTEMIA trial began in September 2024 and is currently ongoing.
What are the next steps for the trial?
A second review by the IDMC is scheduled for early 2026, with recruitment expected to conclude by the end of 2026.
